RELATIONSHIP BETWEEN CIRCULATING BETATROPHIN LEVELS AND INSULIN RESISTANCE IN PREDIABETIC SUBJECTS

nroduction: Betatrophin [also known as RIFL, lipasin, ANGPTL8, TD26] is newly appreciated for its role as a potent inducer of beta cell proliferation in mice. Its expression is increased upon insulin resistance.We here aimed to determine the serum levels of this hormone in prediabetic subjects and to investigate its relationship with metabolic parameters. Material and Methods: The research was designed as a case-control study, in which 42 subjects with prediabetes and 37 with normal glucose tolerance were consecutively recruited, in an attempt to match the groups for age, sex and body mass index (BMI). Serum betatrophin, insulin, C-peptide, fasting blood glucose, HbA1c, high-sensitivity C-reactive protein, and lipid levels were measured. Insulin resistance was evaluated using the HOMA-IR index. Results: Serum betatrophin levels were significantly higher in prediabetic subjects compared with normal glucose-tolerant subjects (p

PREDİYABETİK HASTALARDA BETATROPHİN DÜZEYİ İLE İNSÜLİN DİRENCİ ARASINDAKİ İLİŞK

Giriş: Betatrophin farelerde beta hücrelerinde proliferasyona neden olmakta ve insulin direnci ile sentezi artmaktadır. Araştırmamızda prediyabetik hastalarda serum betatrophin düzeyini incelemeyi ve betatrophinin metabolik parametreler ile ilişkisini incelemeyi amaçladık. Gereç ve Yöntem: Vaka kontrollü olarak planladığımız araştırmamıza; 42 prediyabetik hasta ve yaşı, çinsiyeti ve vücut kitle indexi (VKİ) uygun olan 37 gönüllü glukoz metabolizması normal olan birey alındı. Araştırmaya dâhil edilen bireylerin betatrophin, insulin, C-peptit, açlık kan glikozu, HbA1c, hs-CRP ve lipid düzeyleri ölçüldü. Bireylerin insulin dirençleri HOMA-IR indexi ile hesaplandı. Bulgular: Serum betatrophin düzeyi prediyabetik bireylerde kontrol grubundaki bireylere göre istatistiksel olarak anlamlı yüksek bulundu (p

Kaynakça

American Diabetes Association Standards of medical care in diabetes—2014. DiabetesCare2014; 37(Suppl. 1):14–80.

International Diabetes Federation IDF Diabetes Atlas 6th edition. International Diabetes Federation,2013, Brussels

Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30(3):753-9.

Gerstein HC, Santaguida P, Raina P,Morrison KM, Balion C, Hunt D et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78(3):305-12.

Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol 2013;4:37.

Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab 2009;35(2):77-84.

Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.

Weir GC, Cavelti-Weder C, Bonner-Weir S. Stem cell approaches for diabetes: towards beta cell replacement. Genome Med 2011 3:61.

Ren G, Kim JY, Smas CM .Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012; 303(3):E334-E351.

Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012;424:786-92.

Quagliarini F, Wang Y, Kozlitina J,Grishin NV,Hyde R,Boerwinkle E et al Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A 2012;109(48):19751-6.

Yi P, Park J-S, Melton DA.Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013;153(4):747-58.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.

Espes D, Lau J, Carlsson P-O.Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 2014;57(1):50-3.

Akour A, Kasabri V, Boulatova N, Bustanji Y, Naffa R, Hyasat D et al. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol 2017;54(2):163–70.

Turkon H, Yalcın H, Toprak B, Demirpençe M, Yaşar HY, Colak A. Correlation between Bethatrophin and 25(OH)D Concentrations in a Group of Subjects With Normal and Impaired Glucose Metabolism. Exp Clin Endocrinol Diabetes 2017;125(3):147–50.

Koishi R, Ando Y, Ono M Shimamura M, Yasumo H, Fujiwara T et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 2002;30(2):151-7.

Shimizugawa T, Ono M, Shimamura M Yoshida K, Ando Y, Koishi R, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002;277(37):33742-8.

Köster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE et al.Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005;146(11):4943-50.

Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007;39(4):513-6.

Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.J Clin Invest 2009;119(1):70-9.

Adachi H, Fujiwara Y, Kondo T , Nishikawa T, Ogawa R, Matsumura T, et al. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem Biophys Res Commun 2009;379(4):806-11.

Legry V, Bokor S, Cottel D, Beghin L, Catasta G, Nagy E et al. Associations between common genetic polymorphisms in angiopoietin-like proteins 3 and 4 and lipid metabolism and adiposity in European adolescents and adults.J Clin Endocrinol Metab 2009;94812):5070-7.

Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010;363(23):2220-7.

Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A 2013;110 (40):16109-14.

Kaynak Göster